### Indication
Cerebral ischaemic stroke due to embolic occlusion

**ICD11 code:** 8B11.2

<table>
<thead>
<tr>
<th>INN</th>
<th>Warfarin</th>
</tr>
</thead>
</table>

**Medicine type**
Chemical agent

**List type**
Core (EML), Complementary (EMLc)

**Formulations**
Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt) (EMLc)

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1982 (TRS 685)
- Changed in 1987 (TRS 770)
- Changed in 2007 (TRS 950)
- Changed in 2021 (TRS 1035)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
Therapeutic alternatives to be reviewed (2023)

**Therapeutic alternatives limitations for EMLc**
Therapeutic alternatives to be reviewed (2023)

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
[Warfarin](https://en.wikipedia.org/wiki/Warfarin)

**DrugBank**
[Warfarin](https://www.drugbank.ca/drugs/DB00328)